Feature | April 08, 2011

FDA Approves Aneurysm Treatment System

April 8, 2011 – The U.S. Food and Drug Administration (FDA) has approved an aneurysm treatment system as a Humanitarian Use Device (HDE). NeuroVasx’s cPAX Aneurysm Treatment System can be used to treat large, giant and wide-neck cerebral aneurysms, which are typically the most difficult to treat.

The HDE allows for the treatment of up to 4,000 patients per year in the United States.

"The large, giant and wide-neck cerebral aneurysm population continues to remain the most challenging to treat,” said Christopher Dowd, M.D., clinical professor of neuro-interventional radiology at the University of California at San Francisco and medical director for NeuroVasx. “cPAX will offer physicians an alternative solution that we believe can make a significant impact in treatment and outcome for these patients."

"The longer term stability we have seen in the clinical studies using cPAX in larger aneurysms gives me great confidence in the positive impact this product will have on the care of our patients,” said Ricardo Hanel, M.D., Ph.D., associate professor of neurosurgery at the Mayo Clinic in Jacksonville, Fla., and co-principal investigator in the cPAX Clinical Trial.

A cerebral aneurysm is an abnormal bulge or sac in the wall of an artery in the brain which can be caused by a number of factors including congenital defects, high blood pressure, atherosclerosis, cancer, drug use or head trauma. If a cerebral aneurysm ruptures, it can lead to a hemorrhagic stroke, or bleeding on the brain.

According to the National Institutes of Health, approximately 40 percent of these patients do not survive the first 24 hours. The worldwide incidence of cerebral aneurysms is estimated to be 320,000 annually, approximately 200,000 of which may be treatable with intracranial surgery using minimally invasive techniques.

cPAX is a polymeric strand delivered into the aneurysm using a technique similar to platinum coil technologies. Because of its soft polymeric material, the device is designed to achieve more complete filling of the aneurysm with the probable benefit of greater long-term stability. A significant feature is that it offers the physician the ability to detach the device at any point. The polymeric material also allows for non-invasive CT and MRI scans with little or no artifact for more accurate patient follow-up assessment.

For more information: www.neurovasx.com

Related Content

Medtronic Launches Concerto 3-D Detachable Coil System
News | Embolization devices | October 16, 2017
October 16, 2017 — Medtronic announced the launch of the Concerto 3-D Detachable Coil System at the Cardiovascular an
Artventive EOS embolization device, OCCLUDE post-market surveillance study, enrollment

Image courtesy of ArtVentive Medical Group Inc.

News | Embolization devices | February 24, 2016
ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE...
Penumbra, POD Packing Coil, embolization, peripheral vasculature
Technology | Embolization devices | January 14, 2016
Penumbra Inc. announced the U.S. launch of its new POD Packing Coil, designed as a complementary device for Penumbra’s...
News | Embolization devices | December 17, 2015
ArtVentive Medical Group conducted its first animal study of its next generation of the ArtVentive Endoluminal...
Merit Medical, QuadraSphere Microspheres, FDA approval, expanding indication, hepatoma

Image courtesy of Merit Medical Systems Inc.

Technology | Embolization devices | August 17, 2015
Merit Medical Systems Inc. announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (...
Overlay Init